|
AU2014277804A1
|
|
Glp-1 exendin-4 peptide analogs and uses thereof
|
|
AU2012202081A1
|
|
GLP-1 Exendin-4 peptide analogs and uses thereof
|
|
AU2012200637A1
|
|
Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses
|
|
AU2007202304A2
|
|
Nucleic acid vaccines for prevention of flavivirus infection
|
|
AU2007234733A1
|
|
Antibody compositions and methods for treatment of neoplastic disease
|
|
AU2007200847A1
|
|
Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes and methods for their use
|
|
AU2007212583A1
|
|
Inhibition of HIV infection through chemoprophylaxis
|
|
AU2006251893A1
|
|
Scopolamine for the treatment of depression and anxiety
|
|
AU2005252685A1
|
|
Real-time PCR point mutation assays for detecting HIV-1 resistance to antiviral drugs
|
|
AU2004200813A1
|
|
Transductin-1 and transductin-2 and applications to hereditary deafness
|
|
AU2002356962A1
|
|
Methods for using extracellular adenosine inhibitors and adenosine receptor inhibitors to enhance immune response and inflammation
|
|
AU2002300401A1
|
|
Human papilloma virus anti-sense oligonucleotides
|
|
AU2002317599B2
|
|
GLP-1 exendin-4 peptide analogs and uses thereof
|
|
AU2002258664B2
|
|
Methods of making, using and pharmaceutical formulations comprising 7alpha, 11beta-dimethyl-17beta-hydroxyestra-4, 14-dien-3-one and 17-esters thereof
|
